Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06824103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06824103 · ClinicalTrials.gov record · last posted 2026-06-08

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

StatusRecruiting
PhasePhase 4
Started2025-09-09
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).

Protocol amendment history 1 change detected by DataLookout

2026-06-09
Primary completion moved earlier: 2029-11-29 → 2029-05-10
Trial Details
NCT Number NCT06824103
Lead Sponsor Novartis Pharmaceuticals
Conditions Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Enrollment 50 participants
Start Date 2025-09-09
Primary Completion 2029-05-10 (estimated)
Study Completion 2031-05-23 (estimated)
Updated on ClinicalTrials.gov 2026-06-08